VA
RARE icon

Vident Advisory’s Ultragenyx Pharmaceutical RARE Stock Holding History

Vident Advisory’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,487
Closed -$215K – 1386
2023
Q4 		$215K Buy
+4,487
New +$174K 0.01% 1182

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vident Advisory's RARE Position: Q1 2024 in Review

Vident Advisory sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2024, closing a stake of 4,487 shares — an estimated $215K sold.

Vident Advisory first reported a position in RARE in Q4 2023 and held it in 1 quarter. The position peaked at $215K in Q4 2023. 269 funds tracked by Wall St. Rank hold RARE as of Q1 2024.

  • Vident Advisory reported no remaining Ultragenyx Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Vident Advisory sold 4,487 Ultragenyx Pharmaceutical shares in Q1 2024, an estimated $215K.
  • Vident Advisory first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 1 quarter.
  • Vident Advisory's Ultragenyx Pharmaceutical position peaked at $215K in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2024.

Based on Vident Advisory's 13F filing for Q1 2024, filed 14 May 2024.